Replies to post #122581 on Anavex Life Sciences Corp (AVXL)

[mrplmer]

Thank you for your comments.

[anders2211]

Some have suggested otherwise. But the canceling of the cooperation between Biogen and Anave IS material. AVXL is obligated to file an 8K if Biogen or Anavex were to cancel the cooperation between the two companies.

On Sept 28th Anavex filed this 8K sec filing:
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11643447&RcvdDate=10/21/2016&CoName=ANAVEX%20LIFE%20SCIENCES%20CORP.&FormType=8-K&View=html

"We announced on September 28th that Biogen has signed a material transfer agreement with Anavex to explore ANAVEX 2-73 for a completely different indication, multiple sclerosis, which is the main focus of Biogen’s portfolio. We obviously are excited to work with Biogen to explore the potential of ANAVEX 2-73 in multiple sclerosis."

"Biogen has signed a material transfer agreement with Anavex"

A canceling of the material transfer agreement between the two parties would cause an immediate need to file an 8K because it would be equally a reportable event that constitutes major significance.

Meaning, Biogen and Anavex did not break up as of this date.

IMO if Anavex removed MS from its website its because they are not going to develop it any longer, it could, therefore, mean that Biogen is and we will hear this soon....